(RTTNews) - Tuesday, CSL Seqirus, a business of CSL (CSL.AX), said it has expanded the availability of influenza vaccines in the U.S. following the successful completion of its 2026/27 manufacturing campaign.
(RTTNews) - Tuesday, Immix Biopharma (IMMX) said an interim Phase 2 NEXICART-2 update showed an 89% complete response rate with investigational NXC-201 in relapsed/refractory AL amyloidosis.
(RTTNews) - While reporting financial results for the third quarter on Tuesday, leisure travel company Carnival Corp. & plc (CCL, CUK) provided adjusted earnings guidance for the fourth quarter, and raised adjusted earnings outlook for the full-year 2026.
(RTTNews) - American Express Canada (AXP) on Tuesday unveiled its enhanced Aeroplan co-brand Card portfolio, with new travel, lounge, dining and rewards benefits taking effect January 12, 2027.
(RTTNews) - AbbVie, Inc. (ABBV), a pharmaceutical company, announced a partnership with Valkai, a life sciences artificial intelligence platform, to enhance its AI infrastructure and accelerate scientific innovation.
(RTTNews) - U.S. liquefied natural gas producer Cheniere Energy, Inc. (LNG), announced on Tuesday that its marketing unit has signed a 22-year sale and purchase agreement with Brazil's Petrobras for about 0.8 million tonnes per annum of LNG.
(RTTNews) - Tuesday, Medicus Pharma (MDCX) submitted a streamlined Phase 2b/3 protocol to the FDA for Teverelix in advanced prostate cancer patients at increased cardiovascular risk.
(RTTNews) - Pearson plc (PSO, PSON.L), a British learning and skill enterprise company, on Tuesday said it has agreed to acquire Workera, an AI intelligence platform focused on enterprise assessment and skills verification.
(RTTNews) - AT&T Inc. (T) on Tuesday said it has entered into a multi-year agreement with materials science company Corning Inc. (GLW), valued at more than $3 billion, for the supply of fiber and cable to support its network expansion and growing data demand.
(RTTNews) - Tuesday, uniQure (QURE) reported new data showing its investigational gene therapy AMT-130 continued to slow measures of Huntington's disease progression in patients followed for up to 48 months.
(RTTNews) - Tuesday, Kyowa Kirin (4151.T) said it entered into an exclusive distribution agreement with Knight Therapeutics (GUD.TO) for POTELIGEO (mogamulizumab) in select Latin American countries.